Treatment of the following fungal infections in adults:- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B.- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patient intolerant to itraconazole.- Coccidioidomycosis in patients with disease refractory to amphotericin B, itraconazole or fludonazole or in patient intolerant to these medicinal products.- Zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.These are also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplatic syndrome (MDS) expected to result in prolonged neutropenia who are at high-risk of developing invasive fungal infections.-Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high-risk of developing invasive fungal infections.